NZ503417A - Use of SAG (sensitive to apoptosis gene) in protecting cells from apoptosis - Google Patents

Use of SAG (sensitive to apoptosis gene) in protecting cells from apoptosis

Info

Publication number
NZ503417A
NZ503417A NZ503417A NZ50341798A NZ503417A NZ 503417 A NZ503417 A NZ 503417A NZ 503417 A NZ503417 A NZ 503417A NZ 50341798 A NZ50341798 A NZ 50341798A NZ 503417 A NZ503417 A NZ 503417A
Authority
NZ
New Zealand
Prior art keywords
sag
apoptosis
protein
sensitive
human
Prior art date
Application number
NZ503417A
Other languages
English (en)
Inventor
Yi Sun
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ503417A publication Critical patent/NZ503417A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ503417A 1997-12-19 1998-12-15 Use of SAG (sensitive to apoptosis gene) in protecting cells from apoptosis NZ503417A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6817997P 1997-12-19 1997-12-19
US9984098P 1998-09-11 1998-09-11
PCT/US1998/026705 WO1999032514A2 (en) 1997-12-19 1998-12-15 Sag: sensitive to apoptosis gene

Publications (1)

Publication Number Publication Date
NZ503417A true NZ503417A (en) 2002-12-20

Family

ID=26748669

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503417A NZ503417A (en) 1997-12-19 1998-12-15 Use of SAG (sensitive to apoptosis gene) in protecting cells from apoptosis

Country Status (8)

Country Link
EP (1) EP1044217A2 (xx)
JP (1) JP2001526063A (xx)
KR (1) KR20010033299A (xx)
AU (1) AU765741B2 (xx)
BR (1) BR9813757A (xx)
CA (1) CA2303483A1 (xx)
NZ (1) NZ503417A (xx)
WO (1) WO1999032514A2 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078203B1 (en) 1999-03-31 2006-07-18 The University Of North Carolina At Chapel Hill Isolated DNA encoding cullin regulators ROC1 and ROC2, isolated proteins encoded by the same, and methods utilizing the same
WO2000058472A2 (en) * 1999-03-31 2000-10-05 The University Of North Carolina At Chapel Hill Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same
WO2001046468A2 (en) * 1999-12-21 2001-06-28 Eirx Therapeutics Ltd Screening method for ros-induced apoptosis in a cell
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
EP1299558B1 (en) * 2000-07-07 2006-05-10 Eirx Therapeutics Ltd Screening method
IL156557A0 (en) * 2000-12-22 2004-01-04 Janssen Pharmaceutica Nv Bax-responsive genes for drug target identification in yeast and fungi
CN115345122B (zh) * 2022-08-31 2023-03-17 沐曦科技(北京)有限公司 一种用于仿真的非标准总线协议的芯片验证装置

Also Published As

Publication number Publication date
JP2001526063A (ja) 2001-12-18
CA2303483A1 (en) 1999-07-01
KR20010033299A (ko) 2001-04-25
EP1044217A2 (en) 2000-10-18
BR9813757A (pt) 2000-10-03
WO1999032514A3 (en) 1999-09-10
WO1999032514A2 (en) 1999-07-01
AU1918099A (en) 1999-07-12
AU765741B2 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
Macmillan-Crow et al. Manganese superoxide dismutase in disease
Wong et al. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor
Nehlin et al. Yeast MIG1 repressor is related to the mammalian early growth response and Wilms' tumour finger proteins.
Unoki et al. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility
Kulmburg et al. Specific binding sites in the alcR and alcA promoters of the ethanol regulon for the CREA repressor mediating carbon cataboiite repression in Aspergillus nidulans
Underhill-Day et al. N-terminal rassf family: Rassf7-rassf10
Fritz et al. APE/Ref-1 and the mammalian response to genotoxic stress
Bhawe et al. Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression
Hou et al. Ubiquitin-specific protease 4 promotes TNF-α-induced apoptosis by deubiquitination of RIP1 in head and neck squamous cell carcinoma
St. Clair et al. Overproduction of human Mn‐superoxide dismutase modulates paraquat‐mediated toxicity in mammalian cells
Yan et al. Proteomics characterization of gastrokine 1‐induced growth inhibition of gastric cancer cells
Feussner et al. Isolation of a cDNA coding for an ubiquitin-conjugating enzyme UBC1 of tomato—the first stress-induced UBC of higher plants
Nouman et al. The role of the tumour suppressor p33ING1b in human neoplasia
NZ503417A (en) Use of SAG (sensitive to apoptosis gene) in protecting cells from apoptosis
Banerjee et al. A novel role of gap junction connexin46 protein to protect breast tumors from hypoxia
US8735342B2 (en) Method for treating brain cancer using a novel tumor suppressor gene and secreted factor
Chen et al. CDC73 gene mutations in sporadic ossifying fibroma of the jaws
Bhaduri et al. Rise of TRIM8: a molecule of duality
Liu et al. Molecular cloning and characterization of human Castor, a novel human gene upregulated during cell differentiation
Bataille Melanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity?
WO2001079556A3 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
Zhou et al. Identification and characterization of the novel protein CCDC106 that interacts with p53 and promotes its degradation
Ichikawa et al. Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells
Halachmi et al. Update on genetic events in the pathogenesis of melanoma
He et al. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)